The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Open accessAbstract
Importance: There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies. Objectives: To identify prostate cancer subtypes based on luminal and basal lineage and to determine associations with clinical outcomes and response to treatment. Design, Setting, and Participants: The PAM50 classifier was used to subtype 1567 retrospectively collected (median follow-up, 10 years) and 2215 prospectively collected prostate cancer samples into luminal- and basal-like subtypes. Main Outcomes and Measures: Metastasis, biochemical recurrence, overall survival, prostate cancer–specific survival, associations with biological pathways, and clinicopathologic variables were the main outcomes. Results: Among the 3782 samples, the PAM50 classifier consistently segregated prostate cancer into 3 subtypes in both the retrospective and prospective cohorts: luminal A (retrospective, 538 [34.3%]; prospective, 737 [33.3%]), luminal B (retrospective, 447 [28.5%]; prospective, 723 [32.6%]), and basal (retrospective, 582 [37.1%]; prospective, 755 [34.1%]). Known luminal lineage markers, such as NKX3.1 and KRT18, were enriched in luminal-like cancers, and the basal lineage CD49f signature was enriched in basal-like cancers, demonstrating the connection between these subtypes and established prostate cancer biology. In the retrospective cohort, luminal B prostate cancers exhibited the poorest clinical prognoses on both univariable and multivariable analyses accounting for standard clinicopathologic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate cancer-specific survival [PCSS], 78%; overall survival [OS], 69%), followed by basal prostate cancers (10-year bRFS, 39%; DMFS, 73%; PCSS, 86%; OS, 80%) and luminal A prostate cancers (10-year bRFS, 41%; DMFS, 73%; PCSS, 89%; OS, 82%). Although both luminal-like subtypes were associated with increased androgen receptor expression and signaling, only luminal B prostate cancers were significantly associated with postoperative response to androgen deprivation therapy (ADT) in a subset analysis in our retrospective cohorts (n = 315) matching patients based on clinicopathologic variables (luminal B 10-year metastasis: treated, 33% vs untreated, 55%; nonluminal B 10-year metastasis: treated, 37% vs untreated, 21%; P = .006 for interaction). Conclusions and Relevance: Luminal- and basal-like prostate cancers demonstrate divergent clinical behavior, and patients with luminal B tumors respond better to postoperative ADT than do patients with non–luminal B tumors. These findings contribute novel insight into prostate cancer biology, providing a potential clinical tool to personalize ADT treatment for prostate cancer by predicting which men may benefit from ADT after surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 877
Self-citationA luminal epithelial stem cell that is a cell of origin for prostate cancer
Wang, X., Julio, M. K.-D., Economides, K. D., Walker, D., Yu, H., Halili, M. V., Hu, Y.-P., Price, S. M., Abate-Shen, C., & Shen, M. M. (2009) · Nature · doi:10.1038/nature08361 · Cited by 734
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J., et al. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61700-2 · Cited by 713
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607529 · Cited by 663
Self-citationErho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
Self-citationLoblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Identification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Biomarker: Predictive or Prognostic?
Ballman, K. V. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3651 · Cited by 522
Comprehensive molecular portraits of human breast tumours
McCullough, A. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.013 · Cited by 441
(2016) · Oncotarget · doi:10.18632/oncotarget · Cited by 386
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 375
on behalf of the Transatlantic Prostate Group, Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Møller, H., Reid, J. E., Perry, M., Park, J., Younus, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.39 · Cited by 364
Choi, N., Zhang, B., Zhang, L., Ittmann, M., & Xin, L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.005 · Cited by 341
Karnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Self-citationChia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., Mardis, E., Leung, S., Ung, K., Pritchard, K. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0286 · Cited by 302
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3559-0 · Cited by 286
Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
Self-citationNeo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006019.pub2 · Cited by 257
Agus, D. B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., & Scher, H. I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1869 · Cited by 248
Breast and prostate cancer: more similar than different
Risbridger, G. P., Davis, I. D., Birrell, S. N., & Tilley, W. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2795 · Cited by 246
Ross, A. E., Johnson, M. H., Yousefi, K., Davicioni, E., Netto, G. J., Marchionni, L., Fedor, H. L., Glavaris, S., Choeurng, V., Buerki, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.05.042 · Cited by 243
Self-citationA single-sample microarray normalization method to facilitate personalized-medicine workflows
Piccolo, S. R., Sun, Y., Campbell, J. D., Lenburg, M. E., Bild, A. H., & Johnson, W. E. (2012) · Genomics · doi:10.1016/j.ygeno.2012.08.003 · Cited by 243
Similarities of prostate and breast cancer: Evolution, diet, and estrogens
Coffey, D. S. (2001) · Urology · doi:10.1016/s0090-4295(00)00938-9 · Cited by 227
Zhang, D., Park, D., Zhong, Y., Lu, Y., Rycaj, K., Gong, S., Chen, X., Liu, X., Chao, H.-P., Whitney, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms10798 · Cited by 227
López-Otín, C., & Diamandis, E. P. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0337 · Cited by 215
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K., Mathis, C., Cheng, D., Stuart, J. M., & Witte, O. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518007112 · Cited by 193
Klein, E. A., Yousefi, K., Haddad, Z., Choeurng, V., Buerki, C., Stephenson, A. J., Li, J., Kattan, M. W., Magi-Galluzzi, C., & Davicioni, E. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.036 · Cited by 186
Self-citationNakagawa, T., Kollmeyer, T. M., Morlan, B. W., Anderson, S. K., Bergstralh, E. J., Davis, B. J., Asmann, Y. W., Klee, G. G., Ballman, K. V., & Jenkins, R. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002318 · Cited by 179
Self-citationStoyanova, T., Cooper, A. R., Drake, J. M., Liu, X., Armstrong, A. J., Pienta, K. J., Zhang, H., Kohn, D. B., Huang, J., Witte, O. N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320565110 · Cited by 176
Benzon, B., Zhao, S. G., Haffner, M. C., Takhar, M., Erho, N., Yousefi, K., Hurley, P., Bishop, J. L., Tosoian, J., Ghabili, K., et al. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.49 · Cited by 170
Self-citationLuminal Cells Are Favored as the Cell of Origin for Prostate Cancer
Wang, Z. A., Toivanen, R., Bergren, S. K., Chambon, P., & Shen, M. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.002 · Cited by 168
Den, R. B., Feng, F. Y.-C., Showalter, T. N., Mishra, M. V., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., Kelly, W. K., Birbe, R., McCue, P. A., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.052 · Cited by 149
Self-citationEfficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
Ross, R. W., Xie, W., Regan, M. M., Pomerantz, M. M., Nakabayashi, M., Daskivich, T. J., Sartor, O. A., Taplin, M., Kantoff, P. W., & Oh, W. K. (2008) · Cancer · doi:10.1002/cncr.23304 · Cited by 139
Tomlins, S. A., Alshalalfa, M., Davicioni, E., Erho, N., Yousefi, K., Zhao, S. G., Haddad, Z., Den, R. B., Dicker, A. P., Trock, B. J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.033 · Cited by 136
Self-citationRoss, R. W., Oh, W. K., Xie, W., Pomerantz, M. M., Nakabayashi, M., Sartor, O. A., Taplin, M., Regan, M. M., Kantoff, P. W., & Freedman, M. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6804 · Cited by 111
Freedland, S. J., Choeurng, V., Howard, L. E., Hoedt, A. M. D., du Plessis, M., Yousefi, K., Lam, L. L. C., Buerki, C., Ra, S., Robbins, B. A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.008 · Cited by 80
Self-citationProstate cancer cell lines lack amplification: Overexpression of HER2
Ullén, A., Lennartsson, L., Harmenberg, U., Lennernäs, B., Majumder, K., Holmberg, A., Nilsson, S. F., & Elmberger, G. (2005) · Acta Oncologica · doi:10.1080/02841860510029888 · Cited by 14
Cited by
Widespread and Functional RNA Circularization in Localized Prostate Cancer
Chen, S., Huang, V., Xu, X., Livingstone, J., Soares, F., Jeon, J., Zeng, Y., Hua, J. T., Petricca, J., Guo, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.025 · Cited by 544
Self-citationChen, S., Zhu, G., Yang, Y., Wang, F., Xiao, Y.-T., Zhang, N., Bian, X., Zhu, Y., Yu, Y., Liu, F., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-020-00613-6 · Cited by 502
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Chan, J. M., Zaidi, S., Love, J. R., Zhao, J. L., Setty, M., Wadosky, K. M., Gopalan, A., Choo, Z.-N., Persad, S., Choi, J., et al. (2022) · Science · doi:10.1126/science.abn0478 · Cited by 353
The DNA methylation landscape of advanced prostate cancer
Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sjöström, M., Aggarwal, R., Playdle, D., Liao, A., Alumkal, J. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0648-8 · Cited by 351
Self-citationRecent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Metadata
- Authors
- Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., Den, R. B., Freedland, S. J., Posadas, E., Sandler, H., Klein, E. A., Black, P., Seiler, R., Tomlins, S. A., Chinnaiyan, A. M., Jenkins, R. B., Davicioni, E., Ross, A. E., Schaeffer, E. M., Nguyen, P. L., Carroll, P. R., Karnes, R. J., Spratt, D. E., & Feng, F. Y.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1663
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2613162682
- Cited by
- 308
- References
- 48
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.